The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co.’s
LLY,
+2.81%
obesity drug Zepbound, which in clinical trials helped patients lose up to 48 pounds on average. The drug was approved for adults with obesity or overweight and at least one weight-related condition, such as high blood pressure or high cholesterol, the FDA said. The list price for the drug will be about $1,060, Lilly said in a release Wednesday.
Tirzepatide, the active ingredient in Zepbound, is already approved under the brand name Mounjaro for treatment of Type 2 diabetes. “In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need,” Dr. John Sharretts, director of the FDA’s Division of Diabetes, Lipid Disorders, and Obesity, said in a statement. About 70% of adults in the U.S. have obesity or overweight, and many of them have a weight-related condition, the FDA said. Zepbound is a once-weekly injection, similar to Novo Nordisk’s
NVO,
+0.21%
Wegovy. In clinical trials, abou …
Article Attribution | Read More at Article Source